Disease-A-Month
Volume 52, Issue 11 , Pages 435-440 , November 2006

Drug-Resistant Tuberculosis

References 

  1. Espinal MA, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculous drugs. N Engl J Med. 2001;344:1294–1303
  2. Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculous drug resistance 1994-1997. N Engl J Med. 1998;338:1641–1649
  3. Dye C, Espinal MA, Watt CJ, et al. Worldwide incidence of multidrug-resistance tuberculosis. J Infect Dis. 2002;185:1197–1202
  4. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistance tuberculosis. Am J Respir Crit Care Med. 2004;169:1103–1109
  5. Canetti G, Rist N, Grosset J. Primary drug resistance in tuberculosis. Am Rev Resp Dis. 1964;90:792–799
  6. Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic Acid. BMJ. 1950;2:1073–1085
  7. McDermott W, Mushenheim C, Hadley SJ. Streptomycin in the treatment of tuberculosis in humans. Ann Intern Med. 1947;27:769–822
  8. Tempel CW, Hughes FJ, Mardis RE, et al. Combined intermittent regimes employing streptomycin and para-aminosalicycylic acid in the treatment of pulmonary tuberculosis. Am Rev Tuberc. 1951;63:295–311
  9. Iseman MD. Drug therapy: treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329:784–791[Erratum in N Engl J Med 1993;329:1435.]
  10. Fischl MA, Uttamchandani RB, Daikos GI, et al. An outbreak of tuberculosis caused by multiple-drug resistant tubercle bacilli among patients with HIV infection. Ann Int Med. 1992;117:177–183
  11. Telzak EE, Sepkowitz K, Alepert P, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med. 1995;333:907–912
  12. Maher D, Raviglione M. Global epidemiology of tuberculosis. Clin Chest Med. 2005;26(2):167–182
  13. Granich RM, Oh P, Lewis B, et al. Multidrug resistance among persons with tuberculosis in California, 1994-2003. JAMA. 2005;293:2732–2739
  14. Clark CM, Driver CR, Munsiff SS. Risk factors for drug-resistant tuberculosis among non-US-born persons in New York City. Int J Tuberc Lung Dis. 2005;9:964–969
  15. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistance tuberculosis in Europe: a systematic review. Thorax. 2006;61:158–163
  16. TB Elimination: Treatment of Drug-Resistant Tuberculosis, CDC Document #250112, www.cdc.gov/tb.
  17. Shin SS, Furin JJ, Alcantara F, et al. Emerg Infect Dis. 2006;12:687–688
  18. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000-2004. Morb Mortal Wkly Rep. 2006;55:301–305
  19. Yang Z, Durmaz R, Yang D, et al. Simultaneous detection of isoniazid, rifampin, and ethambutol resistance of Mycobacterium tuberculosis by a single multiplex allele-specific polymerase chain reaction (PCR) assay. Diagn Microbiol Infect Dis. 2005;53:201–208
  20. Makinen J, Marttila HJ, Marjamaki M, et al. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2006;44:350–352
  21. Nahid P, Pai M, Hopewell PC. Advances in the diagnosis and treatment of tuberculosis. Proc Am Thorac Soc. 2006;3:103–110

PII: S0011-5029(06)00091-5

doi: 10.1016/j.disamonth.2006.09.008

Disease-A-Month
Volume 52, Issue 11 , Pages 435-440 , November 2006

Article Tools